Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton's jelly-derived mesenchymal stem cells + teriparatide
- Development stage
- Unknown
- Lead developer
- CHA Biotech
- Modality
- Peptides, Stem Cell Therapies → Cell Therapies
- Administration
- Intramedullary, Intravenous, Subcutaneous
01
Overview
This combination therapy involves the use of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and teriparatide (a recombinant form of parathyroid hormone) for the treatment of osteoporotic vertebral compression fractures (OVCFs). WJ-MSCs are multipotent stem cells that can differentiate into osteoblasts, facilitating new bone formation and reducing fracture susceptibility. Teriparatide acts as an anabolic agent by stimulating osteoblast activity and increasing bone mineral density. In clinical trials led by Dr. Inbo Han at CHA University, the treatment involves an intramedullary injection of WJ-MSCs into the fractured vertebra followed by daily subcutaneous injections of teriparatide. This dual approach aims to enhance bone regeneration and improve clinical outcomes such as pain relief and bone density in postmenopausal women.
- Other names
- WJ-MSCs and TeriparatideWharton's jelly-derived MSCs and PTH 1-34
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on Wharton's jelly-derived mesenchymal stem cells + teriparatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton's jelly-derived mesenchymal stem cells + teriparatide.